Stock Research for ABLYF

ABLYF
Current Price

$23.8500


Latest Update: 2017-12-13 12:47:00

High
$ 23.8500
Low
$ 23.8500
Close
$ 23.8500
Volume
300
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ABLYF Stock Chart & Research Data

The ABLYF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABLYF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABLYF Due diligence Resources & Stock Charts

The ABLYF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABLYF Detailed Price Forecast - CNN Money CNN View ABLYF Detailed Summary - Google Finance
Yahoo View ABLYF Detailed Summary - Yahoo! Finance Zacks View ABLYF Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ABLYF Trends & Analysis - Trade-Ideas Barrons View ABLYF Major Holders - Barrons
NASDAQ View ABLYF Call Transcripts - NASDAQ Seeking View ABLYF Breaking News & Analysis - Seeking Alpha
Spotlight View ABLYF Annual Report - CompanySpotlight.com OTC Report View ABLYF OTC Short Report - OTCShortReport.com
TradeKing View ABLYF Fundamentals - TradeKing Charts View ABLYF SEC Filings - Bar Chart
WSJ View Historical Prices for ABLYF - The WSJ Morningstar View Performance/Total Return for ABLYF - Morningstar
MarketWatch View the Analyst Estimates for ABLYF - MarketWatch CNBC View the Earnings History for ABLYF - CNBC
StockMarketWatch View the ABLYF Earnings - StockMarketWatch MacroAxis View ABLYF Buy or Sell Recommendations - MacroAxis
Bullish View the ABLYF Bullish Patterns - American Bulls Short Pains View ABLYF Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ABLYF Stock Mentions - StockTwits PennyStocks View ABLYF Stock Mentions - PennyStockTweets
Twitter View ABLYF Stock Mentions - Twitter Invest Hub View ABLYF Investment Forum News - Investor Hub
Yahoo View ABLYF Stock Mentions - Yahoo! Message Board Seeking Alpha View ABLYF Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ABLYF - SECform4.com Insider Cow View Insider Transactions for ABLYF - Insider Cow
CNBC View ABLYF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABLYF - OTC Markets
Yahoo View Insider Transactions for ABLYF - Yahoo! Finance NASDAQ View Institutional Holdings for ABLYF - NASDAQ


Stock Charts

FinViz View ABLYF Stock Insight & Charts - FinViz.com StockCharts View ABLYF Investment Charts - StockCharts.com
BarChart View ABLYF Stock Overview & Charts - BarChart Trading View View ABLYF User Generated Charts - Trading View


Latest Financial News for ABLYF

Ablynx NV breached its 50 day moving average in a Bullish Manner : ABLYF-US : December 5, 2017
Posted on Tuesday December 05, 2017

Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ablynx NV. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)


Ablynx NV – Value Analysis (US OTC:ABLYF) : October 27, 2017
Posted on Friday October 27, 2017

Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Ablynx NV a score of 39. Our analysis is based on comparing Ablynx NV with the following peers – Affimed N.V., Gilead Sciences, Inc., Proteon Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. (AFMD-US, GILD-US, PRTO-US and IONS-US). Investment Outlook Ablynx NV has a fundamental score of 39 and ... Read more (Read more...)


ETFs with exposure to Ablynx NV : October 26, 2017
Posted on Thursday October 26, 2017

Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ablynx NV Here are 5 ETFs with the largest exposure to ABLYF-US. Comparing the performance and risk of Ablynx NV with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)


Ablynx NV breached its 50 day moving average in a Bearish Manner : ABLYF-US : October 26, 2017
Posted on Thursday October 26, 2017

Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Ablynx NV. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)


Ablynx NV (ABLX) Reports Additional Results from Phase III HERCULES Study with ...
StreetInsider.com - Dec 12, 2017
The presentation is available on the Ablynx website under Events & Presentations. Dr Robert K. Zeldin, Chief Medical Officer at Ablynx, commented: "The reduced use of plasma exchange and shorter time in the ICU and hospital further demonstrate the ...

Ablynx NV (ABLX) Says Results from Hercules Study of Caplacizumab Selected for ...
StreetInsider.com - Nov 21, 2017
Ablynx NV (Nasdaq: ABLX) today announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six abstracts for oral presentation in the late-breaking abstracts session at the 59th Annual Meeting of the ...

Ablynx - Catalyst Next Month, Good Midterm Buy
Seeking Alpha - Sep 13, 2017
Ablynx is preparing for a potential first launch of its lead drug candidate caplacizumab in 1H2018, with phase 3 data readout possibly next month.

Ablynx: Not Ready Just Yet
Seeking Alpha - Jul 12, 2017
Ablynx (OTCPK:ABLYF), the Belgian biotech engaged in the discovery and development of nanobodies, performed rather poorly in this year's first quarter.

Enter a stock symbol to view the stock details.